HTL 0030310
Alternative Names: HTL-0030310Latest Information Update: 02 Apr 2024
At a glance
- Originator Sosei Heptares
- Developer Nxera Pharma
- Class Peptides; Small molecules
- Mechanism of Action Somatostatin receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Endocrine disorders
Most Recent Events
- 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
- 28 Mar 2022 No recent reports of development identified for phase-I development in Endocrine-disorders(In volunteers) in United Kingdom (SC, Injection)
- 03 Sep 2020 Sosei Heptares completes a phase I trial in Endocrine disorders (In volunteers) in the UK (SC) in September 2020 (EudraCT2018-003169-33) (NCT03847207)